CU-06 is under clinical development by Curacle and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CU-06’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CU-06 overview
CU-06 is under development for the treatment of diabetic macular edema, wet macular degeneration, ulcerative colitis and colon cancer. It is administered through oral route. The drug candidate acts by targeting NF-kB inflammatory signaling pathway.
The drug candidate was also under development for the treatment of diabetic retinopathy, stroke, acute respiratory distress syndrome, myocardial infarction, hereditary angioedema, unstable angina, Crohn's disease and acute lung injury.
Curacle overview
Curacle focuses on the development of new drugs with technology for incurable diseases caused by the aging process and damage to blood vessels. The company offers products such as development of therapeutics for intractable vascular and metabolic diseases. Curacle’s researches and develops synthetic drugs CU06, CU01, and natural drug CU03 as new drugs for intractable vascular diseases. The company’s drugs are used for diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). It markets its products throughout Korea. Curacle is headquartered in Seoul, South Korea.
For a complete picture of CU-06’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
